Skip to main content
Erschienen in: Infection 4/2020

19.05.2020 | Original Paper

Blood culture sampling rate in hospitalised children as a quality indicator for diagnostic stewardship

verfasst von: André Ricardo Araujo da Silva, Elena Jaszkowski, Tilmann Schober, Ulrich von Both, Melanie Meyer-Buehn, Ariana Hübner, Johannes Hübner

Erschienen in: Infection | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Recommendations regarding the optimal number of blood cultures in children are not available. The aim of this article is to describe the correlation between blood culture (BC) rates and laboratory-confirmed bloodstream infection (LCBSI) rates, on different paediatric wards of a tertiary-care centre in Germany.

Methods

We conducted a retrospective cohort study in a paediatric university hospital, from 1st January to 31st December 2018. All blood cultures collected from neonatal (NICU) and paediatric intensive-care units (PICU), haematology/oncology, and general paediatric wards were included. There were no exclusion criteria. BC taken/1000 patients-days (BC rates/BCR) and LCBSI/1000 patient-days at risk (LCBSI rates) were calculated for each unit.

Results

A total of 6040 patients were admitted to the hospital with 3114 of them into wards studied. Of the 3072 BCs collected, 200 (6.5%) were positive. Collection of BCs was performed in 51/77 (66.2%) of admitted patients on NICU, in 151/399 (37.8%) of PICU patients, in 163/755 (21.6%) of haematology/oncology patients, and in 281/1883 (14.9%) of children on general paediatric wards. Gram-positive bacteria were the most commonly detected organisms in blood cultures from all wards with exception of NICU. The BCR in NICU, PICU, haematology/oncology wards, and general wards were 61.6, 196.2, 358.4, and 52.3, respectively. Excluding commensal pathogens and possible contaminations, the LCBSI rates in the same units were 2.4, 5.6, 4.4, and 1.0, respectively.

Conclusion

We found different BCR values according the ward studied, being higher in patients with high risk of bloodstream infection such as haematology/oncology patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Connell TG, Rele M, Cowley D, et al. How reliable is a negative blood culture result? Volume of blood submitted for culture in routine practice in a children's hospital. Pediatrics. 2007;119:891–6.CrossRef Connell TG, Rele M, Cowley D, et al. How reliable is a negative blood culture result? Volume of blood submitted for culture in routine practice in a children's hospital. Pediatrics. 2007;119:891–6.CrossRef
2.
Zurück zum Zitat Brown DR, Kutler D, Rai B, et al. Bacterial concentration and blood volume required for a positive blood culture. J Perinatol. 1995;15:157–9.PubMed Brown DR, Kutler D, Rai B, et al. Bacterial concentration and blood volume required for a positive blood culture. J Perinatol. 1995;15:157–9.PubMed
4.
Zurück zum Zitat Gonsalves WI, Cornish N, Moore M, et al. Effects of volume and site of blood draw on blood culture results. J Clin Microbiol. 2009;47:3482–5.CrossRef Gonsalves WI, Cornish N, Moore M, et al. Effects of volume and site of blood draw on blood culture results. J Clin Microbiol. 2009;47:3482–5.CrossRef
5.
Zurück zum Zitat Verstraete EH, Mahieu L, d'Haese J, et al. Blood culture indications in critically ill neonates: a multicenter prospective cohort study. Eur J Pediatr. 2018;177:1565–72.CrossRef Verstraete EH, Mahieu L, d'Haese J, et al. Blood culture indications in critically ill neonates: a multicenter prospective cohort study. Eur J Pediatr. 2018;177:1565–72.CrossRef
6.
Zurück zum Zitat Polin RA, Committee on Fetus and Newborn. Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics. 2012;129:1006–155.CrossRef Polin RA, Committee on Fetus and Newborn. Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics. 2012;129:1006–155.CrossRef
7.
Zurück zum Zitat Verani JR, McGee L, Schrag SJ. Division of bacterial diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC) Prevention of perinatal group B streptococcal disease–revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010;59:1–36.PubMed Verani JR, McGee L, Schrag SJ. Division of bacterial diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC) Prevention of perinatal group B streptococcal disease–revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010;59:1–36.PubMed
8.
Zurück zum Zitat National Collaborating Centre for Women’s and Children’s Health (UK). Antibiotics for early-onset neonatal infection: antibiotics for the prevention and treatment of early-onset neonatal infection. London: RCOG Press; 2012. National Collaborating Centre for Women’s and Children’s Health (UK). Antibiotics for early-onset neonatal infection: antibiotics for the prevention and treatment of early-onset neonatal infection. London: RCOG Press; 2012.
9.
Zurück zum Zitat Kohn Loncarica G, Fustiñana A, Jabornisky R. Recommendations for the management of pediatric septic shock in the first hour (part one). Arch Argent Pediatr. 2019;117:e14–e23.PubMed Kohn Loncarica G, Fustiñana A, Jabornisky R. Recommendations for the management of pediatric septic shock in the first hour (part one). Arch Argent Pediatr. 2019;117:e14–e23.PubMed
10.
Zurück zum Zitat Bradley JS, Byington CL, Shah SS, et al. Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the pediatric infectious diseases society and the infectious diseases society of America. Clin Infect Dis. 2011;53:e25–e76.CrossRef Bradley JS, Byington CL, Shah SS, et al. Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the pediatric infectious diseases society and the infectious diseases society of America. Clin Infect Dis. 2011;53:e25–e76.CrossRef
11.
Zurück zum Zitat Schifman RB, Strand CL, Braun E, et al. Solitary blood cultures as a quality assurance indicator. Qual Assur Util Rev. 1991;6:132–7.CrossRef Schifman RB, Strand CL, Braun E, et al. Solitary blood cultures as a quality assurance indicator. Qual Assur Util Rev. 1991;6:132–7.CrossRef
12.
Zurück zum Zitat Schelonka RL, Chai MK, Yoder BA, et al. Volume of blood required to detect common neonatal pathogens. J Pediatr. 1996;129:275–8.CrossRef Schelonka RL, Chai MK, Yoder BA, et al. Volume of blood required to detect common neonatal pathogens. J Pediatr. 1996;129:275–8.CrossRef
13.
Zurück zum Zitat Baron EJ, Weinstein MP, Dunne WM Jr, et al. Cumitech 1c, Blood cultures IV. Washington, DC: ASM Press; 2005. Baron EJ, Weinstein MP, Dunne WM Jr, et al. Cumitech 1c, Blood cultures IV. Washington, DC: ASM Press; 2005.
14.
Zurück zum Zitat Seifert H, Abele-Horn M, Fätkenheuer G, et al. Blutkulturdiagnostik: Sepsis, Endokarditis, Katheterinfektionen. In: Podbielski A, Herrmann M, Kniehl E, Mauch H, Russmann H, editors. Mikrobiologisch-infektiologische Qualitätsstandards (MiQ). München: Elsevier; 2007. Seifert H, Abele-Horn M, Fätkenheuer G, et al. Blutkulturdiagnostik: Sepsis, Endokarditis, Katheterinfektionen. In: Podbielski A, Herrmann M, Kniehl E, Mauch H, Russmann H, editors. Mikrobiologisch-infektiologische Qualitätsstandards (MiQ). München: Elsevier; 2007.
15.
Zurück zum Zitat Schifman RB, Bachner P, Howanitz PJ. Blood culture quality improvement: a College of American Pathologists Q-Probes study involving 909 institutions and 289 572 blood culture sets. Arch Pathol Lab Med. 1996;120:999–1002.PubMed Schifman RB, Bachner P, Howanitz PJ. Blood culture quality improvement: a College of American Pathologists Q-Probes study involving 909 institutions and 289 572 blood culture sets. Arch Pathol Lab Med. 1996;120:999–1002.PubMed
16.
Zurück zum Zitat Karch A, Castell S, Schwab F, et al. Proposing an empirically justified reference threshold for blood culture sampling rates in intensive care units. J Clin Microbiol. 2015;53:648–52.CrossRef Karch A, Castell S, Schwab F, et al. Proposing an empirically justified reference threshold for blood culture sampling rates in intensive care units. J Clin Microbiol. 2015;53:648–52.CrossRef
18.
Zurück zum Zitat Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. Lancet. 2017;390:1770–80.CrossRef Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. Lancet. 2017;390:1770–80.CrossRef
20.
Zurück zum Zitat Murni IK, Duke T, Daley AJ, et al. True pathogen or contamination: validation of blood cultures for the diagnosis of nosocomial infections in a developing country. J Trop Pediatr. 2018;64:389–94.CrossRef Murni IK, Duke T, Daley AJ, et al. True pathogen or contamination: validation of blood cultures for the diagnosis of nosocomial infections in a developing country. J Trop Pediatr. 2018;64:389–94.CrossRef
21.
Zurück zum Zitat Salih KM, El-Samani el F, Bilal JA, et al. Clinical and laboratory potential predictors of blood culture positivity in under five children with clinically severe Pneumonia-Khartoum-Sudan. J Clin Diagn Res. 2015;9:SC04–7.PubMedPubMedCentral Salih KM, El-Samani el F, Bilal JA, et al. Clinical and laboratory potential predictors of blood culture positivity in under five children with clinically severe Pneumonia-Khartoum-Sudan. J Clin Diagn Res. 2015;9:SC04–7.PubMedPubMedCentral
23.
Zurück zum Zitat Jakacka N, Snarski E, Mekuria S. Prevention of Iatrogenic anemia in critical and neonatal care. Adv Clin Exp Med. 2016;25:191–7.CrossRef Jakacka N, Snarski E, Mekuria S. Prevention of Iatrogenic anemia in critical and neonatal care. Adv Clin Exp Med. 2016;25:191–7.CrossRef
24.
Zurück zum Zitat Elzi L, Babouee B, Vögeli N, et al. How to discriminate contamination from bloodstream infection due to coagulase-negative staphylococci: a prospective study with 654 patients. Clin Microbiol Infect. 2012;18:E355–E361361.CrossRef Elzi L, Babouee B, Vögeli N, et al. How to discriminate contamination from bloodstream infection due to coagulase-negative staphylococci: a prospective study with 654 patients. Clin Microbiol Infect. 2012;18:E355–E361361.CrossRef
25.
Zurück zum Zitat Modi N, Doré CJ, Saraswatula A, et al. A case definition for national and international neonatal bloodstream infection surveillance. Arch Dis Child Fetal Neonatal Ed. 2009;94:F8–12.CrossRef Modi N, Doré CJ, Saraswatula A, et al. A case definition for national and international neonatal bloodstream infection surveillance. Arch Dis Child Fetal Neonatal Ed. 2009;94:F8–12.CrossRef
26.
Zurück zum Zitat Woods-Hill CZ, Fackler J, Nelson McMillan K, Ascenzi J, Martinez DA, Toerper MF. Association of a clinical practice guideline with blood culture use in critically ill children. JAMA Pediatr. 2017;171:157–64.CrossRef Woods-Hill CZ, Fackler J, Nelson McMillan K, Ascenzi J, Martinez DA, Toerper MF. Association of a clinical practice guideline with blood culture use in critically ill children. JAMA Pediatr. 2017;171:157–64.CrossRef
27.
Zurück zum Zitat Flett KB, Ozonoff A, Graham DA, Sandora TJ, Priebe GP. Impact of mandatory public reporting of central line-associated bloodstream infections on blood culture and antibiotic utilization in pediatric and neonatal intensive care units. Infect Control Hosp Epidemiol. 2015;36:878–85.CrossRef Flett KB, Ozonoff A, Graham DA, Sandora TJ, Priebe GP. Impact of mandatory public reporting of central line-associated bloodstream infections on blood culture and antibiotic utilization in pediatric and neonatal intensive care units. Infect Control Hosp Epidemiol. 2015;36:878–85.CrossRef
28.
Zurück zum Zitat Orrett FA, Changoor E. Bacteremia in children at a regional hospital in Trinidad. Int J Infect Dis. 2007;11:145–51.CrossRef Orrett FA, Changoor E. Bacteremia in children at a regional hospital in Trinidad. Int J Infect Dis. 2007;11:145–51.CrossRef
Metadaten
Titel
Blood culture sampling rate in hospitalised children as a quality indicator for diagnostic stewardship
verfasst von
André Ricardo Araujo da Silva
Elena Jaszkowski
Tilmann Schober
Ulrich von Both
Melanie Meyer-Buehn
Ariana Hübner
Johannes Hübner
Publikationsdatum
19.05.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 4/2020
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-020-01439-y

Weitere Artikel der Ausgabe 4/2020

Infection 4/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.